Duchesne M, et al: Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder. J Neuropathol Exp Neurol. 2018 Feb 2;1-8
Touchon J, et al: Direct double-blind analysis arguing for synergistic therapeutic effect of a fixed low-dose combination of acamprosate and baclofen in patients with AD. 2017 Nov 1-4. CTAD Poster #LBP32BIS
Wang W, et al: A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients. PLoS One. 2017 Jan 17;12(1)
Attarian S, et al: Erratum to: An exploratory randomized double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orph J Rare Dis. 2016 Jul 7;11.92
Toulorge D, et al : Molecular changes in the postmortem parkinsonian brain. J Neurochem. 2016 Oct;139 Suppl 1:27-58
Hajj R, et al: Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease. Scientific Reports (Nature) 2015 Nov 6:16084
Mandel J, et al: A meta-analysis of randomized doubleblind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Orph J Rare Dis. 2015 Jun 13;74
Chumakov I, et al: Combining two repurposed drugs as a promising approach for Alzheimer’s disease therapy. Scientific Reports (Nature) 2015 Jan 8;7608
Attarian S, et al: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of Baclofen, Naltrexone and Sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orph J Rare Dis. 2014 Dec 18:199
Chumakov I, et al: Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orph J Rare Dis. 2014 Dec 10;201
